Teva's Planned Generic Infringes Mylan Patents, Judge Says

Law360, Los Angeles (March 24, 2014, 7:27 PM EDT) -- A West Virginia federal judge ruled Friday that claims asserted by Mylan Inc. in a patent-infringement suit over Teva Pharmaceutical USA Inc.'s planned generic version of Mylan's respiratory illness drug Perforomist weren't invalid due to anticipation, obviousness or enablement.

Upholding the validity of Mylan's four patents at issue, U.S. District Judge Irene M. Keeley said in Friday's findings of fact and conclusions of law granting judgment in favor of the plaintiffs that Teva didn't prove that the asserted claims in the patents-at-issue were invalid and thus...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.